Innovative Solutions for Treatment and Improvement of Quality of Life
About Sun Pharma
Vision & Values
Milestones & Recognitions
Board of Directors
חדשנות
איכות
מוצרים
Responsibility
CSR
Sustainability
Environment, Health and Safety (EHS)
Covid-19
Investors
Disclosures under Regulation 46
Policies
Financial Information
Board Meeting & Financial Results
Annual Reports
Shareholding Pattern
Quarterly Financials, Transcripts & Earnings Call Recordings
Investor Presentations
Newspaper Advertisements
Annual Reports of Subsidiary Companies
Disclosure Under Regulation 30
Secretarial Compliance Report
Credit Rating
Investor Contact
Annual Return
Committees of the Board
Financials
Investor Presentations
Annual Reports
Annual Reports of Subsidiary Companies
Shareholders’ Information
Stock Price Information
Statutory Communications
Scheme of Arrangement
Policies
Buyback 2020 Daily Reports
Credit Rating
Memorandum of Association
Investor Services
FAQs
Archives
Sun Pharma – Ranbaxy Merger
Ranbaxy Archives
Quarterly Results
Corporate Governance
Annual Reports
Presentations
Shareholding Pattern
Unclaimed Dividend
Committees of the Board
Media
Press Releases
Stories
Media Contacts
קריירה
Worldwide
North America
USA
Canada
Mexico
South America
Brazil
Peru
Asia Pacific
India
Bangladesh
Thailand
Malaysia and Singapore
Myanmar
Sri Lanka
Japan
China
Israel
Europe
Denmark
Finland
France
Germany
Hungary
Italy
Norway
Poland
Romania
Spain
Sweden
Switzerland
The Netherlands
The United Kingdom & Ireland
Middle East
UAE
Africa
Morocco
Nigeria
South Africa
Egypt
Oceania
Australia & New Zealand
CIS
Russia
Ukraine
צור קשר
בחרו עמוד
Product Quality Complaint Form
Top
Important Notice
As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023
it is mandatory
for all the shareholders holding shares in
physical form
to update their KYC and other details.
Learn More
CLOSE
English
